Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (551-560 of 567) with videos related to

Pageof 57
Sort By:
Cell|April 13, 1999
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromesM F McDermott, I Aksentijevich, J Galon, et al.
The New England Journal of Medicine|June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Nature Reviews. Rheumatology|January 25, 2018
Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaborationAndrew P Cope, Michael R Barnes, Alexandra Belson, et al.
Nature Reviews. Rheumatology|December 8, 2017
The RA-MAP Consortium: a working model for academia-industry collaborationAndrew P Cope, Michael R Barnes, Alexandra Belson, et al.
Cancer Cell|March 12, 2021
Progressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A Braun, Kelly Street, Kelly P Burke, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Clinical Genitourinary Cancer|December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
Arthritis and Rheumatism|September 18, 2003
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypesEbun Aganna, Linda Hammond, Philip N Hawkins, et al.
Pageof 57

Showing results (551-560 of 567) with videos related to

Sort By:
Pageof 57
Cell|April 13, 1999
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromesM F McDermott, I Aksentijevich, J Galon, et al.
The New England Journal of Medicine|June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.
Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.
Cell Reports. Medicine|January 4, 2023
CD8<sup>+</sup> T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapyMahrukh A Huseni, Lifen Wang, Joanna E Klementowicz, et al.
Nature Reviews. Rheumatology|January 25, 2018
Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaborationAndrew P Cope, Michael R Barnes, Alexandra Belson, et al.
Nature Reviews. Rheumatology|December 8, 2017
The RA-MAP Consortium: a working model for academia-industry collaborationAndrew P Cope, Michael R Barnes, Alexandra Belson, et al.
Cancer Cell|March 12, 2021
Progressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A Braun, Kelly Street, Kelly P Burke, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Clinical Genitourinary Cancer|December 6, 2016
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM<sup>SM</sup>Joseph I Clark, Michael K K Wong, Howard L Kaufman, et al.
Arthritis and Rheumatism|September 18, 2003
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypesEbun Aganna, Linda Hammond, Philip N Hawkins, et al.
Pageof 57